190 related articles for article (PubMed ID: 32176823)
1. Biallelic loss of FAM46C triggers tumor growth with concomitant activation of Akt signaling in multiple myeloma cells.
Kanasugi J; Hanamura I; Ota A; Karnan S; Lam VQ; Mizuno S; Wahiduzzaman M; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Takami A
Cancer Sci; 2020 May; 111(5):1663-1675. PubMed ID: 32176823
[TBL] [Abstract][Full Text] [Related]
2. FAM46C inhibits cell proliferation and cell cycle progression and promotes apoptosis through PTEN/AKT signaling pathway and is associated with chemosensitivity in prostate cancer.
Ma L; He H; Jiang K; Jiang P; He H; Feng S; Chen K; Shao J; Deng G
Aging (Albany NY); 2020 Apr; 12(7):6352-6369. PubMed ID: 32283544
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J
Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427
[TBL] [Abstract][Full Text] [Related]
4. Loss of
Zhu YX; Shi CX; Bruins LA; Jedlowski P; Wang X; Kortüm KM; Luo M; Ahmann JM; Braggio E; Stewart AK
Cancer Res; 2017 Aug; 77(16):4317-4327. PubMed ID: 28619709
[No Abstract] [Full Text] [Related]
5. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
Yamaji M; Ota A; Wahiduzzaman M; Karnan S; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Haniuda M
Cancer Med; 2017 Nov; 6(11):2646-2659. PubMed ID: 28960945
[TBL] [Abstract][Full Text] [Related]
6. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
8. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo.
Ge NL; Rudikoff S
Oncogene; 2000 Aug; 19(36):4091-5. PubMed ID: 10962569
[TBL] [Abstract][Full Text] [Related]
9. Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model.
Kim C; Lee JH; Ko JH; Chinnathambi A; Alharbi SA; Shair OHM; Sethi G; Ahn KS
Biomolecules; 2019 Jul; 9(7):. PubMed ID: 31284669
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.
Manni S; Carrino M; Manzoni M; Gianesin K; Nunes SC; Costacurta M; Tubi LQ; Macaccaro P; Taiana E; Cabrelle A; Barilà G; Martines A; Zambello R; Bonaldi L; Trentin L; Neri A; Semenzato G; Piazza F
Oncotarget; 2017 Feb; 8(9):14604-14619. PubMed ID: 28099937
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
12. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
[TBL] [Abstract][Full Text] [Related]
13. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
Chen P; Wen X; Wang B; Hou D; Zou H; Yuan Q; Yang H; Xie J; Huang H
Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644
[TBL] [Abstract][Full Text] [Related]
14. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
[TBL] [Abstract][Full Text] [Related]
15. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
16. FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma.
Herrero AB; Quwaider D; Corchete LA; Mateos MV; García-Sanz R; Gutiérrez NC
J Cell Mol Med; 2020 Apr; 24(7):4171-4182. PubMed ID: 32141701
[TBL] [Abstract][Full Text] [Related]
17. The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma.
Wang L; Lin N; Li Y
Oncol Rep; 2019 Mar; 41(3):1678-1690. PubMed ID: 30664164
[TBL] [Abstract][Full Text] [Related]
18. FAM46C and FNDC3A Are Multiple Myeloma Tumor Suppressors That Act in Concert to Impair Clearing of Protein Aggregates and Autophagy.
Manfrini N; Mancino M; Miluzio A; Oliveto S; Balestra M; Calamita P; Alfieri R; Rossi RL; Sassoè-Pognetto M; Salio C; Cuomo A; Bonaldi T; Manfredi M; Marengo E; Ranzato E; Martinotti S; Cittaro D; Tonon G; Biffo S
Cancer Res; 2020 Nov; 80(21):4693-4706. PubMed ID: 32963011
[TBL] [Abstract][Full Text] [Related]
19. Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines.
Hausmann S; Brandt E; Köchel C; Einsele H; Bargou RC; Seggewiss-Bernhardt R; Stühmer T
PLoS One; 2015; 10(4):e0122689. PubMed ID: 25837824
[TBL] [Abstract][Full Text] [Related]
20. A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration.
Amachi R; Hiasa M; Teramachi J; Harada T; Oda A; Nakamura S; Hanson D; Watanabe K; Fujii S; Miki H; Kagawa K; Iwasa M; Endo I; Kondo T; Yoshida S; Aihara KI; Kurahashi K; Kuroda Y; Horikawa H; Tanaka E; Matsumoto T; Abe M
Oncotarget; 2016 Oct; 7(43):70447-70461. PubMed ID: 27626482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
